Orogen Royalties Inc
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2020-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.organon.com
- Introduction
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
An Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Chronic Urticaria (MK-4117-201)
- First Posted Date
- 2013-08-06
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 239
- Registration Number
- NCT01916967
Study of the Efficacy and Safety of MK-0476 in Japanese Pediatric Participants With Seasonal Allergic Rhinitis (MK-0476-519)
- First Posted Date
- 2013-05-20
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 220
- Registration Number
- NCT01857063
Study of the Safety and Pharmacokinetics of Montelukast (MK-0476) in the Treatment of Japanese Pediatric Participants With Perennial Allergic Rhinitis (MK-0476-520)
Phase 3
Completed
- Conditions
- Perennial Allergic Rhinitis
- Interventions
- First Posted Date
- 2013-05-14
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 87
- Registration Number
- NCT01852812
Efficacy and Safety of Oral NOMAC-E2 in Indian Women (P07057/MK-8175A-017)
Phase 3
Withdrawn
- Conditions
- Contraception
- Interventions
- First Posted Date
- 2012-11-08
- Last Posted Date
- 2022-02-16
- Lead Sponsor
- Organon and Co
- Registration Number
- NCT01723579
A Study of the Efficacy and Safety of Corifollitropin Alfa (MK-8962) in Combination With Human Chorionic Gonadotropin (hCG) in Adult Men With Hypogonadotropic Hypogonadism (HH) (P07937)
Phase 3
Completed
- Conditions
- HypogonadismHypogonadotropic Hypogonadism
- Interventions
- First Posted Date
- 2012-10-18
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 18
- Registration Number
- NCT01709331
A Dose-Finding Study to Evaluate Ovarian Function and Vaginal Bleeding in Next Generation Rings (P06109/MK-8175A/MK-8342B-012)
Phase 2
Completed
- Conditions
- Contraception
- Interventions
- First Posted Date
- 2012-10-18
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 666
- Registration Number
- NCT01709318
Finasteride (MK-0906) and Male Breast Cancer - A Register-Based Nested Case-Control Study (MK-0906-162/2003.021).
Completed
- Conditions
- Male Breast Cancer
- First Posted Date
- 2012-10-10
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 575216
- Registration Number
- NCT01703520
Etoricoxib Prescribing Patterns and Adverse Events of Interest in Primary Care in the United Kingdom (MK-0663-162 AM1)
Completed
- Conditions
- OsteoarthritisAnkylosing SpondylitisGoutArthritisRheumatoid Arthritis
- Interventions
- First Posted Date
- 2012-09-14
- Last Posted Date
- 2022-02-18
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 79189
- Registration Number
- NCT01685424
A Study to Evaluate the Safety of Combination Montelukast/Loratadine in Mexican Participants With Allergic Rhinitis (MK-0476A-484)
Phase 3
Completed
- Conditions
- Allergic Rhinitis
- Interventions
- Drug: Placebo
- First Posted Date
- 2012-08-28
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 69
- Registration Number
- NCT01673620
A Study to Evaluate the Effect of Contraceptive Vaginal Rings on Primary Dysmenorrhea (P08257/MK-8175A/MK-8342B-057)
Phase 2
Completed
- Conditions
- Dysmenorrhea
- Interventions
- First Posted Date
- 2012-08-22
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 439
- Registration Number
- NCT01670656